Anti-HER2 antibody-drug conjugate

US10118972B2 · kind B2 · utility

Assignee

• DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

• Hiroyuki Naito · Tokyo, JP
• Yusuke Ogitani · Tokyo, JP
• Takeshi Masuda · Tokyo, JP
• Takashi Nakada · Tokyo, JP
• Masao Yoshida · Tokyo, JP
• Shinji Ashida · Tokyo, JP
• Koji Morita · Tokyo, JP
• Hideki Miyazaki · Tokyo, JP
• Yuji Kasuya · Tokyo, JP
• Ichiro Hayakawa · Tokyo, JP
• Yuki Abe · Tokyo, JP

Key dates

• Filing date: Jul 28, 2016
• Grant date: Nov 6, 2018
• Expiry date: Jul 28, 2036

Classification

• Technology area (CPC —): General

Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(═O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.